283 related articles for article (PubMed ID: 18560335)
1. Prodrugs in cardiovascular therapy.
Sandros MG; Sarraf CB; Tabrizian M
Molecules; 2008 May; 13(5):1156-78. PubMed ID: 18560335
[TBL] [Abstract][Full Text] [Related]
2. Amino acids as promoieties in prodrug design and development.
Vig BS; Huttunen KM; Laine K; Rautio J
Adv Drug Deliv Rev; 2013 Oct; 65(10):1370-85. PubMed ID: 23099277
[TBL] [Abstract][Full Text] [Related]
3. Prodrug strategy for enhancing drug delivery via skin.
Fang JY; Leu YL
Curr Drug Discov Technol; 2006 Sep; 3(3):211-24. PubMed ID: 17311566
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
5. Prodrug strategies for antihypertensives.
Dhaneshwar SS; Sharma M; Patel V; Desai U; Bhojak J
Curr Top Med Chem; 2011; 11(18):2299-317. PubMed ID: 21671866
[TBL] [Abstract][Full Text] [Related]
6. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.
Dahan A; Khamis M; Agbaria R; Karaman R
Expert Opin Drug Deliv; 2012 Aug; 9(8):1001-13. PubMed ID: 22703376
[TBL] [Abstract][Full Text] [Related]
7. Current prodrug design for drug discovery.
Hsieh PW; Hung CF; Fang JY
Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
[TBL] [Abstract][Full Text] [Related]
8. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
9. Prodrug approaches for CNS delivery.
Rautio J; Laine K; Gynther M; Savolainen J
AAPS J; 2008; 10(1):92-102. PubMed ID: 18446509
[TBL] [Abstract][Full Text] [Related]
10. Prodrugs--from serendipity to rational design.
Huttunen KM; Raunio H; Rautio J
Pharmacol Rev; 2011 Sep; 63(3):750-71. PubMed ID: 21737530
[TBL] [Abstract][Full Text] [Related]
11. Prodrugs: effective solutions for solubility, permeability and targeting challenges.
Hu L
IDrugs; 2004 Aug; 7(8):736-42. PubMed ID: 15334306
[TBL] [Abstract][Full Text] [Related]
12. Different concepts of drug delivery in disease entities.
Serafin A; Stańczak A
Mini Rev Med Chem; 2009 Apr; 9(4):481-97. PubMed ID: 19356126
[TBL] [Abstract][Full Text] [Related]
13. Lipidic prodrug approach for improved oral drug delivery and therapy.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Med Res Rev; 2019 Mar; 39(2):579-607. PubMed ID: 30320896
[TBL] [Abstract][Full Text] [Related]
14. Prodrugs: design and clinical applications.
Rautio J; Kumpulainen H; Heimbach T; Oliyai R; Oh D; Järvinen T; Savolainen J
Nat Rev Drug Discov; 2008 Mar; 7(3):255-70. PubMed ID: 18219308
[TBL] [Abstract][Full Text] [Related]
15. Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy.
Ding C; Chen C; Zeng X; Chen H; Zhao Y
ACS Nano; 2022 Sep; 16(9):13513-13553. PubMed ID: 36048467
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs: a challenge for the drug development.
Zawilska JB; Wojcieszak J; Olejniczak AB
Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in prodrugs as drug delivery systems.
Lin C; Sunkara G; Cannon JB; Ranade V
Am J Ther; 2012 Jan; 19(1):33-43. PubMed ID: 21150770
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
19. Rational design and development of colon-specific prodrugs.
Dhaneshwar SS; Vadnerkar G
Curr Top Med Chem; 2011; 11(18):2318-45. PubMed ID: 21671865
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of dendrimer prodrugs.
Kojima C
Expert Opin Drug Metab Toxicol; 2015; 11(8):1303-15. PubMed ID: 26028253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
